Department of Neurosurgery, University of Pennsylvania Health System, Philadelphia, USA.
Deparment of Radiation Oncology, University of Pennsylvania Health System, Philadelphia, USA.
Clin Neurol Neurosurg. 2021 Dec;211:107016. doi: 10.1016/j.clineuro.2021.107016. Epub 2021 Nov 4.
Brain metastases are the most common central nervous system (CNS) tumors, occurring in 300,000 people per year in the US. While there are immediate local benefits to surgical resection for dominant lesions, including reduction of tumor burden and edema, the survival benefits of surgical resection, over radiosurgery, remains unclear.
The University of Pennsylvania Health System database was retrospectively reviewed for patients presenting with multiple brain metastases from 1/1/16-8/31/18 with one dominant lesion > 2 cm in diameter, who underwent initial treatment with either resection of the dominant lesion or Gamma Knife radiosurgery (GKS). Inclusion criteria were age > 18, > 1 brain metastasis, and presence of a dominant lesion (>2 cm). We analyzed factors associated with mortality.
129 patients were identified (surgery=84, GKS=45). The median number of intracranial metastases was 3 (IQR: 2-5). The median diameter of the largest lesion was 31 mm (IQR: 25-38) in the surgery group vs 21 mm (IQR: 20-24) in the GKS group (p < 0.001). Mortality did not differ between surgery and GKS patients (69.1% vs 77.8%, p = 0.292). In a multivariate survival analysis, there was no difference in mortality between the surgery and GKS cohorts (aHR: 1.35, 95% CI: 0.74-2.45 p = 0.32). Pre-operative KPS (aHR: 0.97, 95% CI: 0.95-0.99, p = 0.004), CNS radiotherapy (aHR: 0.33, 95% CI: 0.19-0.56 p < 0.001), chemotherapy (aHR: 0.27, 95% CI: 0.15-0.47, p < 0.001), and immunotherapy (aHR: 0.41, 95% CI: 0.25-0.68, p = 0.001) were associated with decreased mortality.
In our institution, patients with multiple brain metastases and one symptomatic dominant lesion demonstrated similar survival after GKS when compared with up-front surgical resection of the dominant lesion.
脑转移瘤是最常见的中枢神经系统(CNS)肿瘤,在美国每年有 30 万人患有这种疾病。对于直径大于 2 厘米的优势病灶,手术切除可立即减轻肿瘤负荷和水肿,具有明显的局部获益,但手术切除相对于伽玛刀放射外科(GKS)的生存获益仍不清楚。
本研究回顾性分析了 2016 年 1 月 1 日至 2018 年 8 月 31 日期间在宾夕法尼亚大学健康系统就诊的 129 例脑转移瘤患者的临床资料,这些患者具有一个直径大于 2 厘米的优势病灶,初始治疗方案为手术切除或 GKS。纳入标准为年龄大于 18 岁,颅内存在多个转移瘤,且具有一个优势病灶(直径大于 2 厘米)。我们分析了与死亡率相关的因素。
共纳入 129 例患者(手术组 84 例,GKS 组 45 例)。颅内转移瘤中位数为 3 个(IQR:2-5)。手术组最大病灶的中位数直径为 31mm(IQR:25-38),GKS 组为 21mm(IQR:20-24)(p<0.001)。手术组和 GKS 组患者的死亡率无差异(69.1%vs77.8%,p=0.292)。多变量生存分析显示,手术组和 GKS 组的死亡率无差异(aHR:1.35,95%CI:0.74-2.45,p=0.32)。术前 KPS(aHR:0.97,95%CI:0.95-0.99,p=0.004)、中枢神经系统放疗(aHR:0.33,95%CI:0.19-0.56,p<0.001)、化疗(aHR:0.27,95%CI:0.15-0.47,p<0.001)和免疫治疗(aHR:0.41,95%CI:0.25-0.68,p=0.001)与死亡率降低相关。
在我们的机构中,对于具有一个症状性优势病灶的多发性脑转移瘤患者,与初始手术切除优势病灶相比,GKS 治疗后的生存情况相似。